
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is a promising clinical-stage biotechnology company with a protein degradation platform that has the potential to revolutionize the treatment of debilitating and life-threatening diseases. With positive data for their lead candidate ARV-102, showing 72% reduction in LRRK2 levels in Parkinson's patients, and upcoming data for their other product candidates, Arvinas is positioned for potential success in the future. Furthermore, the company's strong financial position, with a partnership for ex-US commercialization and a diverse pipeline, adds to its appeal as a long-term investment option.
Bears say
Arvinas is facing strong competition in the market, especially in the LRRK2 inhibitor space with Biogen's BIIB122. Although ARV-102 shows slightly better results in terms of LRRK2 and urine BMP reductions, its sample size is smaller and it may not be enough to differentiate itself from other competitors. The positive results in CSF LRRK2 and pathway biomarkers reduction are consistent with prior healthy volunteer data, but the company still has a long way to go before validating the LRRK2 pathway broadly.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares